Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure

Positive

AI Analysis

Summary

Ratio Therapeutics closed a $70 million Series C financing round, bringing total capital raised to over $240 million to advance its clinical-stage radiopharmaceuticals pipeline and expand manufacturing infrastructure for cancer treatment.

Importance:6/10

Sentiment:

0.70

financingSeries Cradiopharmaceuticalscapital raisemanufacturing expansion

Read the original article

Published by PR Newswire Pharma on July 31, 2026 12:00 PM

Read Original